Theravance Biopharma: Failed Phase 3 Trial, Strategic Review
Theravance Biopharma began a strategic review after a failed Phase 3 trial.
NASDAQ
Theravance Biopharma, Inc.
TBPH
1 article
$883M Market cap · 2026-08-21
Investor Letters
Letters that discuss TBPH.
- Laughing Water Capital H1 2026 H1 2026 +33.6% ANAB $1.7BAVNS $1.2BGSK $105BLFCR $172M
